July 13, 2018 -- The U.S. Food and Drug Administration is alerting health care professionals and patients of a voluntary recall of several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure. This recall is due to an impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled products. However, not all products containing valsartan are being recalled. NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. The presence of NDMA was unexpected and is thought to be related to changes in the way the active substance was manufactured.
The FDA’s review is ongoing and has included investigating the levels of NDMA in the recalled products, assessing the possible effect on patients who have been taking them and what measures can be taken to reduce or eliminate the impurity from future batches produced by the company.
“The FDA is committed to maintaining our gold standard for safety and efficacy. That includes our efforts to ensure the quality of drugs and the safe manner in which they’re manufactured,” said FDA Commissioner Scott Gottlieb, M.D. “When we identify lapses in the quality of drugs and problems with their manufacturing that have the potential to create risks to patients, we’re committed to taking swift action to alert the public and help facilitate the removal of the products from the market. As we seek the removal of certain drug products today, our drug shortages team is also working hard to ensure patients’ therapeutic needs are met in the United States with an adequate supply of unaffected medications.”
VALSARTAN Why Weren't We Warned?
July 13, 2018 -- The U.S. Food and Drug Administration is alerting health care professionals and patients of a voluntary recall of several drug products containing the active ingredient valsartan ...
Valsartan Recall FAQs
Attorneys at Wagner Reese are hard at work investigating the failures that allowed the contamination of Valsartan medication to go unnoticed for years. We have compiled a list of the top seven ...
Taxotere Lawsuit | 2018 News & Settlements, File Now
Though patients were warned of these potential side effects, many breast cancer survivors have since taken action against Sanofi, sometimes referred to as Sanofi-Aventis, for downplaying how severe some of these side effects may be, especially after marketing the drug as being more effective than other types of chemotherapy.
Media Moves Toward ZERO DIVERSITY In Talking Points ...
Mike Papantonio is an American attorney and television and radio talk show host. He is past president of The National Trial Lawyers, the most prestigious trial lawyer association in America; and is one of the few living attorneys inducted into the Trial Lawyer Hall of Fame.
Trump-Supporting Business Owner Lays Off Staff, Begs ...
It’s not like people weren’t out there warning you every, single day. I mean hell, it’s not like the President didn’t warn you he was going to do these things. I mean to his credit, Donald Trump has actually kept a lot of his promises.
Pharmaceutical Drug Lawsuits - masstorts.com
Talcum Powder Lawsuit – long-used for daily feminine hygiene, talcum powder products like Baby Powder and Shower to Shower have been associated with dangerous and deadly ovarian cancer and victims want to know why they weren’t warned.
Transvaginal Mesh Lawsuit - MDL Status & Legal Claims
Thousands of women who received transvaginal mesh implants to treat a conditions called pelvic organ prolapse (POP) and stress urinary incontinence (SUI) claim they weren’t warned that the devices could cause severe pain, organ damage and other complications.
Abilify Lawsuit | 2018 Status, Settlements & How to File Today
Hundreds of Abilify lawsuits may settle soon. ... They have filed lawsuits against Bristol-Myers Squibb and Otsuka Pharmaceutical Co. saying they weren’t adequately warned. More than 1,600 pending Abilify lawsuits may end in a settlement soon. ... We appreciate your feedback. One of our content team members will be in touch with you soon.